摘要
来源于患者的人类诱导多能干细胞(hiPSCs)的生成和遗传精确校正在再生医学上有巨大的潜力。这种靶向定位的遗传操作,现在可以利用核酸的基因剪辑来实现。在这里,我们介绍了使用CCR5-具体TALENS分别提取CF(纯合子突变CFTRΔF508)和Type II GD [合子葡糖脑苷脂酶( GBA ) 1448T > C区变异] 病人的成纤维细胞的囊性纤维化( CF )和高雪氏病( GD )hiPSCs的生成过程。在源于病人的疾病特异性初级成纤维细胞的内源性CCR5位点特定添加loxP的两侧的Oct4 / Sox2的/ Klf4的/ LIN28 / Nanog的/绿色荧光蛋白基因盒的诱导再编程,从而引发双方monoallele (杂)和biallele CCR5修饰hiPSCs。随后的捐助盒切除是通过用Cre处理由CCR5修饰的CF和GD的hiPSCs细胞完成的。我们还证明了在患者特异性hiPSCs的内源性HBB基因座的镰状细胞病( SCD)突变的位点特异性校正[ TNC1线是纯合的突变的β-珠蛋白等位基因( βS / βS ) ] ,使用HBB特异性TALENS 。 SCD-校正hiPSC线表明突变βS的基因转化到野生型βA在HBB等位基因之一,而另一个等位基因仍然是一个突变体的表型。使用Cre从SCD校正hiPSC系切除loxP的侧翼的DNA盒后,我们获得了二级杂βS / βA人iPS细胞。二级杂βS / βA人iPS细胞相比未校正( βS / βS )SCD分化为类红细胞时的人iPS细胞,转录表达野生型( βA )到30-40 %的水平 。此外,我们还表明, TALEN介导的针对特定疾病的人类诱导多能干细胞的产生和遗传校正在密切相关的位点没有引起任何脱靶突变。
关键词: 囊性纤维化(CF) 、高雪氏病(GD ) ,基因更正, 镰状细胞病(SCD ),转录activatorlike效应核酸( TALENS ),锌指核酸酶(ZFN ) 。
Current Gene Therapy
Title:TALEN-Mediated Generation and Genetic Correction of Disease-Specific Human Induced Pluripotent Stem Cells
Volume: 14 Issue: 6
Author(s): Sivaprakash Ramalingam, Narayana Annaluru, Karthikeyan Kandavelou and Srinivasan Chandrasegaran
Affiliation:
关键词: 囊性纤维化(CF) 、高雪氏病(GD ) ,基因更正, 镰状细胞病(SCD ),转录activatorlike效应核酸( TALENS ),锌指核酸酶(ZFN ) 。
摘要: Generation and precise genetic correction of patient-derived hiPSCs have great potential in regenerative medicine. Such targeted genetic manipulations can now be achieved using gene-editing nucleases. Here, we report generation of cystic fibrosis (CF) and Gaucher’s disease (GD) hiPSCs respectively from CF (homozygous for CFTRΔF508 mutation) and Type II GD [homozygous for β-glucocerebrosidase (GBA) 1448T>C mutation] patient fibroblasts, using CCR5- specific TALENs. Site-specific addition of loxP-flanked Oct4/Sox2/Klf4/Lin28/Nanog/eGFP gene cassette at the endogenous CCR5 site of patient-derived disease-specific primary fibroblasts induced reprogramming, giving rise to both monoallele (heterozygous) and biallele CCR5-modified hiPSCs. Subsequent excision of the donor cassette was done by treating CCR5-modified CF and GD hiPSCs with Cre. We also demonstrate site-specific correction of sickle cell disease (SCD) mutations at the endogenous HBB locus of patient-specific hiPSCs [TNC1 line that is homozygous for mutated β- globin alleles (βS/βS)], using HBB-specific TALENs. SCD-corrected hiPSC lines showed gene conversion of the mutated βS to the wild-type βA in one of the HBB alleles, while the other allele remained a mutant phenotype. After excision of the loxP-flanked DNA cassette from the SCD-corrected hiPSC lines using Cre, we obtained secondary heterozygous βS/βA hiPSCs, which express the wild-type (βA) transcript to 30-40% level as compared to uncorrected (βS/βS) SCD hiPSCs when differentiated into erythroid cells. Furthermore, we also show that TALEN-mediated generation and genetic correction of disease-specific hiPSCs did not induce any off-target mutations at closely related sites.
Export Options
About this article
Cite this article as:
Ramalingam Sivaprakash, Annaluru Narayana, Kandavelou Karthikeyan and Chandrasegaran Srinivasan, TALEN-Mediated Generation and Genetic Correction of Disease-Specific Human Induced Pluripotent Stem Cells, Current Gene Therapy 2014; 14 (6) . https://dx.doi.org/10.2174/1566523214666140918101725
DOI https://dx.doi.org/10.2174/1566523214666140918101725 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements